Subscribe

  • How Can We Help You?

    Global Problem Solving from Covington: Deal with Complex Problems Anywhere in the World

Trzeciak_Alex_1000x714_ENV

Alexander Trzeciak

Associate

Washington +1 202 662 5447

  • About
  • Representative Matters
  • Credentials
  • About

    Alexander Trzeciak is an associate in the firm’s Washington, DC office, where he focuses his practice on patent litigation in a broad range of technologies, with an emphasis on pharmaceutical patents. Coming to the law with an educational background in chemical engineering, Alex has experience in all stages of litigation, from pre-litigation through expert discovery, pretrial, and trial. He has argued discovery disputes and at pretrial conferences, and he has conducted direct examination of a key technical expert at trial. Alex has represented both pharmaceutical and high-technology companies, including before United States district courts, the United States International Trade Commission, and the Patent Trial and Appeal Board.

    Areas of Expertise

  • Practices and Industries
  • Representative Matters
    • Represented AstraZeneca defending its Tagrisso® drug product against accusations of patent infringement brought by Pfizer and Puma Biotech in the District of Delaware.
    • Represented Amgen in Hatch-Waxman patent litigation against nearly 20 generic drug companies in the District of New Jersey involving Amgen’s Otezla® product.
    • Represented Intercept Pharmaceuticals against generic manufacturers involving Intercept’s Ocaliva® product in the District of Delaware.
    • Represented LEO Pharmaceuticals in Hatch-Waxman litigation in the District of Delaware involving LEO’s Enstilar® Product.
    • Represented a medical device company in a section 337 investigation relating to radiofrequency microneedle technology.
    • Represented a leading pharmaceutical manufacturer in Hatch-Waxman litigation concerning patents related to an antipsychotic drug product.
    • Represented a leading pharmaceutical manufacturer in the District of New Jersey concerning patents directed to a medication used to treat non-small cell lung cancer.
    • Representation of UCB in Hatch-Waxman litigation filed in the District of Delaware involving UCB’s Vimpat® product, used in the treatment of epilepsy and other CNS disorders.
    • Representation of Shire LLC in Hatch-Waxman cases in the District of Massachusetts and the District of New Jersey, concerning Shire’s Adderall XR® product for the treatment of ADHD.
    • Representation of Anacor Pharmaceuticals in inter partes review proceedings challenging two Orange Book-listed patents for Kerydin®, Anacor’s topical antifungal drug.

    Areas of Expertise

  • Credentials
    Education
    • Duke University School of Law, J.D., 2014
        • magna cum laude
        • Order of the Coif
        • Duke Law Journal, Online Editor
    • Vanderbilt University, B.E., 2011
        • summa cum laude
        • Chemical Engineering
    Bar Admissions
    • District of Columbia
    • Texas
    Judicial Clerkship
    • Hon. Timothy B. Dyk, U.S. Court of Appeals, Federal Circuit, 2016 - 2017
    • Hon. Leonard Davis, U.S. District Court, Eastern District of Texas, 2014 - 2015

    Areas of Expertise

News and Insights

Events